Traveller's diarrhoea vaccine transdermal - Intercell USA

Drug Profile

Traveller's diarrhoea vaccine transdermal - Intercell USA

Alternative Names: Escherichia coli vaccine transdermal - Intercell USA; ETEC vaccine - Intercell USA; Prophylactic TD vaccine patch; Transcutaneous ETEC vaccine - Intercell USA; Vaccine patch for traveller's diarrhoea - Intercell USA

Latest Information Update: 16 May 2014

Price : $50

At a glance

  • Originator Iomai Corporation
  • Developer Intercell USA
  • Class Adjuvants
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Escherichia coli infections; Traveller's diarrhoea

Most Recent Events

  • 13 Dec 2010 Discontinued - Phase-III for Escherichia coli infections in European Union (Transdermal)
  • 12 Dec 2010 Discontinued - Phase-II for Escherichia coli infections in India (Transdermal)
  • 12 Dec 2010 Discontinued - Phase-II for Traveller's diarrhoea in India (Transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top